MSCM
PTCT icon

McElhenny Sheffield Capital Management’s PTC Therapeutics PTCT Stock Holding History

McElhenny Sheffield Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-16
Closed -$611 – 486
2022
Q4 		$611 Buy
+16
New +$665 ﹤0.01% 618

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

McElhenny Sheffield Capital Management's PTCT Position: Q1 2023 in Review

McElhenny Sheffield Capital Management sold out of PTC Therapeutics (PTCT) in Q1 2023, closing a stake of 16 shares — an estimated $611 sold.

McElhenny Sheffield Capital Management first reported a position in PTCT in Q4 2022 and held it in 1 quarter. The position peaked at $611 in Q4 2022. 202 funds tracked by Wall St. Rank hold PTCT as of Q1 2023.

  • McElhenny Sheffield Capital Management reported no remaining PTC Therapeutics position as of Q1 2023 after selling out during the quarter.
  • McElhenny Sheffield Capital Management sold 16 PTC Therapeutics shares in Q1 2023, an estimated $611.
  • McElhenny Sheffield Capital Management first reported a position in PTC Therapeutics in Q4 2022 and held it in 1 quarter.
  • McElhenny Sheffield Capital Management's PTC Therapeutics position peaked at $611 in Q4 2022.
  • 202 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2023.

Based on McElhenny Sheffield Capital Management's 13F filing for Q1 2023, filed 13 Apr 2023.